Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00161642 · ClinicalTrials.gov registry record · Phase 1

Study Evaluating CMD-193 in Advanced Malignant Solid Tumors

A Phase 1 study of Neoplasms, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 1
Development phase
54
Enrollment target
3
Study locations

NCT00161642 is a Phase 1 study of Neoplasms that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 54 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00161642, a Phase 1 study of Neoplasms, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
54 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of CMD-193. Preliminary information about how a person's body processes CMD-193 and how CMD-193 affects tumors will also be collected.

Conditions Studied

Neoplasms

Interventions

  • DRUG CMD-193

Study Locations (3)

New Hampshire

  • - Lebanon

Pennsylvania

  • - Philadelphia

Tennessee

  • - Nashville

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2004-11
Est. Completion 2007-07
Phase Phase 1

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00161642

The ClinicalTrials.gov registry entry for NCT00161642 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which CMD-193 is the first listed.

NCT00161642 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New Hampshire, Pennsylvania, Tennessee.

Frequently Asked Questions

What is clinical trial NCT00161642 about?

NCT00161642 is a clinical study titled "Study Evaluating CMD-193 in Advanced Malignant Solid Tumors". The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of CMD-193. Preliminary information about how a person's body processes CMD-193 and how CMD-193 affects tumors will also be collected.

What is the current status of trial NCT00161642?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2004-11. Estimated completion is 2007-07.

What conditions does trial NCT00161642 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT00161642?

The interventions under investigation include: CMD-193 (DRUG).

Who is sponsoring clinical trial NCT00161642?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00161642 being conducted?

This trial has 3 study locations across New Hampshire, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

New Hampshire

All trials with a study site in New Hampshire

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.